Procaps Group (PROC) Competitors $1.71 -0.04 (-2.29%) As of 01/17/2025 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends PROC vs. PLRX, BCAX, PRTA, DNTH, CRMD, QURE, ETNB, CGEM, LENZ, and PHARShould you be buying Procaps Group stock or one of its competitors? The main competitors of Procaps Group include Pliant Therapeutics (PLRX), Bicara Therapeutics (BCAX), Prothena (PRTA), Dianthus Therapeutics (DNTH), CorMedix (CRMD), uniQure (QURE), 89bio (ETNB), Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Procaps Group vs. Pliant Therapeutics Bicara Therapeutics Prothena Dianthus Therapeutics CorMedix uniQure 89bio Cullinan Therapeutics LENZ Therapeutics Pharming Group Pliant Therapeutics (NASDAQ:PLRX) and Procaps Group (NASDAQ:PROC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment. Does the media prefer PLRX or PROC? In the previous week, Pliant Therapeutics had 5 more articles in the media than Procaps Group. MarketBeat recorded 6 mentions for Pliant Therapeutics and 1 mentions for Procaps Group. Procaps Group's average media sentiment score of 0.92 beat Pliant Therapeutics' score of 0.22 indicating that Procaps Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Procaps Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, PLRX or PROC? Procaps Group has higher revenue and earnings than Pliant Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M431.73-$161.34M-$3.34-3.36Procaps Group$409.92MN/A$42.54MN/AN/A Which has more volatility and risk, PLRX or PROC? Pliant Therapeutics has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, Procaps Group has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Do institutionals and insiders hold more shares of PLRX or PROC? 97.3% of Pliant Therapeutics shares are owned by institutional investors. 6.4% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 19.9% of Procaps Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community favor PLRX or PROC? Pliant Therapeutics received 72 more outperform votes than Procaps Group when rated by MarketBeat users. Likewise, 74.26% of users gave Pliant Therapeutics an outperform vote while only 37.50% of users gave Procaps Group an outperform vote. CompanyUnderperformOutperformPliant TherapeuticsOutperform Votes7574.26% Underperform Votes2625.74% Procaps GroupOutperform Votes337.50% Underperform Votes562.50% Is PLRX or PROC more profitable? Procaps Group's return on equity of 0.00% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -48.91% -41.09% Procaps Group N/A N/A N/A Do analysts prefer PLRX or PROC? Pliant Therapeutics currently has a consensus price target of $40.50, indicating a potential upside of 261.28%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Pliant Therapeutics is more favorable than Procaps Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Procaps Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryPliant Therapeutics beats Procaps Group on 9 of the 15 factors compared between the two stocks. Get Procaps Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PROC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROC vs. The Competition Export to ExcelMetricProcaps GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E RatioN/A9.9189.4217.36Price / SalesN/A309.211,240.0477.11Price / Cash3.0461.4443.7535.97Price / BookN/A6.055.314.79Net Income$42.54M$154.90M$122.54M$225.00M7 Day Performance-2.84%1.35%1.42%2.37%1 Month Performance-31.87%0.41%2.51%4.40%1 Year Performance-60.60%3.08%25.30%20.10% Procaps Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROCProcaps GroupN/A$1.71-2.3%N/A-60.6%$0.00$409.92M0.005,500Positive NewsGap UpPLRXPliant Therapeutics3.767 of 5 stars$11.77-2.0%$40.50+244.1%-32.9%$716.25M$1.58M-3.5290BCAXBicara TherapeuticsN/A$12.99-9.7%$43.00+231.0%N/A$706.86MN/A0.0032News CoveragePRTAProthena2.4187 of 5 stars$13.13+0.6%$46.50+254.2%-58.3%$706.51M$133.35M-5.29130Positive NewsDNTHDianthus Therapeutics2.0525 of 5 stars$23.04-4.8%$46.43+101.5%+67.4%$681.92M$5.37M-9.2280Short Interest ↑CRMDCorMedix2.614 of 5 stars$11.12-0.6%$15.67+40.9%+273.3%$674.73M$12.26M-13.7330QUREuniQure3.9484 of 5 stars$13.79-0.4%$33.88+145.6%+153.2%$672.17M$28.59M-2.78500Positive NewsETNB89bio2.1414 of 5 stars$6.31-3.1%$30.33+380.7%-42.8%$669.66MN/A-2.1740Analyst ForecastShort Interest ↑CGEMCullinan Therapeutics2.0296 of 5 stars$11.04-1.3%$31.67+186.8%-10.9%$642.84M$18.94M-3.8930LENZLENZ Therapeutics2.1449 of 5 stars$23.200.0%$35.40+52.6%N/A$638.02MN/A0.00110Short Interest ↑Positive NewsPHARPharming Group2.5709 of 5 stars$9.37-3.5%$27.00+188.2%-17.5%$635.61M$285.75M-36.04280Positive NewsGap Down Related Companies and Tools Related Companies Pliant Therapeutics Alternatives Bicara Therapeutics Alternatives Prothena Alternatives Dianthus Therapeutics Alternatives CorMedix Alternatives uniQure Alternatives 89bio Alternatives Cullinan Therapeutics Alternatives LENZ Therapeutics Alternatives Pharming Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PROC) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Procaps Group S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Procaps Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PROC Stock Alerts